$159.13−1.07 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Novartis (NVS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~6.5%/yr (FY21→FY25), net margin 24.6%, and free cash flow (~$15.2B) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Returns vs FCF (134%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($B)▲9.6%
56.7
FY21→FY25CAGR +6.5%/yr
Net income ($B)▲16.9%
13.9
FY21→FY25CAGR −12.7%/yr
Free cash flow ($B)▲10.4%
15.2
FY21→FY25CAGR +5.1%/yr
Diluted EPS▲21.8%
7.15
buyback-liftedCAGR −9.4%/yr
What the receipts whisper · what a headline number hides
Share count
−14.6%
2.2bn → 1.9bn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$3.9B
steady at 6.9% of revenue (+2.3% YoY).
Returns vs FCF
134%
$20.4B returned vs $15.2B of FCF in FY25. The gap comes off the balance sheet (see net cash).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
25¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 73.3% → 75.8%. Net margin 24.6% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 56,674.0 | 56,674.0 | 51,722.0 | 46,660.0 | 43,461.0 | 43,974.0 | ▲9.6% | +6.5% |
Cost of revenue | 13,699.0 | 13,699.0 | 12,827.0 | 12,472.0 | 11,582.0 | 11,735.0 | ▲6.8% | +3.9% |
Gross profit | 42,975.0 | 42,975.0 | 38,895.0 | 34,188.0 | 31,879.0 | 32,239.0 | ▲10.5% | +7.5% |
Research & development | 11,200.0 | 11,200.0 | 10,022.0 | 11,371.0 | 9,172.0 | 8,641.0 | ▲11.8% | +6.7% |
Selling, general & admin | 13,248.0 | 13,248.0 | 12,566.0 | 12,517.0 | 12,193.0 | 12,827.0 | ▲5.4% | +0.8% |
Total operating expenses | 25,331.0 | 25,331.0 | 24,351.0 | 24,419.0 | 23,933.0 | 22,183.0 | ▲4.0% | +3.4% |
Operating incomefeeds ROC rank | 17,644.0 | 17,644.0 | 14,544.0 | 9,769.0 | 7,946.0 | 10,056.0 | ▲21.3% | +15.1% |
Other income, net | −1,292.0 | −1,292.0 | −904.0 | −646.0 | −769.0 | 14,474.0 | — | — |
Pretax income | 16,352.0 | 16,352.0 | 13,640.0 | 9,123.0 | 7,177.0 | 24,530.0 | ▲19.9% | −9.6% |
Income tax | 2,385.0 | 2,385.0 | 1,701.0 | 551.0 | 1,128.0 | 1,625.0 | ▲40.2% | +10.1% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 13,950.0 | 13,950.0 | 11,937.0 | 14,858.0 | 6,955.0 | 24,015.0 | ▲16.9% | −12.7% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 7.15 | 7.15 | 5.87 | 7.10 | 3.17 | 10.63 | ▲21.8% | −9.4% |
Diluted shares (bn) | 1.91 | 1.91 | 1.98 | 2.04 | 2.12 | 2.23 | ▼3.4% | −3.9% |
| Margins | ||||||||
Gross margin69th pct in Healthcare | 75.8% | 75.8% | 75.2% | 73.3% | 73.4% | 73.3% | ▲0.6pp | +2.5pp |
Operating margin | 31.1% | 31.1% | 28.1% | 20.9% | 18.3% | 22.9% | ▲3.0pp | +8.3pp |
Net margin89th pct in Healthcare | 24.6% | 24.6% | 23.1% | 31.8% | 16.0% | 54.6% | ▲1.5pp | −30.0pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-04 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Novartis' revenue last fiscal year?
Novartis reported revenue of $56.7B in fiscal 2025, up 9.6% from fiscal 2024.
What was Novartis' net income?
Novartis reported net income of $13.9B in fiscal 2025, a net margin of 24.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

